Most coverage of the November hemp change is written for people who sell intoxication. If you sell aroma, the same statute reads very differently, and the difference is worth understanding properly rather than optimistically.
Read what the statute actually limits
Section 781 of Public Law 119-37 takes effect 365 days after the Act was signed on 12 November 2025. Every operative limit in it is written about cannabinoids.
The threshold test covers “total tetrahydrocannabinols concentration (including tetrahydrocannabinolic acid)”. The finished-product exclusion covers “greater than 0.4 milligrams combined total per container” of total THC plus “any other cannabinoids that have similar effects (or are marketed to have similar effects) on humans or animals as a tetrahydrocannabinol”.
Terpenes appear nowhere in any of it. They are not cannabinoids, they do not produce tetrahydrocannabinol-like effects, and the drafting never reaches for them.
The statute goes further in the other direction. Its separate definition of industrial hemp protects the stalk, the fiber, the grain, the seed, the oil, the cake, the nut, the hull “or any other non-cannabinoid derivative, mixture, preparation, or manufacture”. The legislative interest is in cannabinoids and consistently not in the rest of the plant’s chemistry.
The asymmetry that matters commercially
A cap of 0.4mg combined per container does not shrink the intoxicating hemp category. It removes it as a federal product class, because 0.4mg per container is below a single conventional serving.
What that leaves behind is every reason people bought these products that was not intoxication. Flavor. Aroma. The sensory character of a profile. The ritual. Those were always a meaningful share of the purchase and they were rarely the thing anyone optimised for, because effect was easier to sell.
The demand does not vanish with the cannabinoid. It relocates to whatever still delivers the sensory part.
What this actually asks of a formulator
Three things get harder, and they are worth naming because “just do terpenes” is not a plan.
The profile has to carry the product alone. When a cannabinoid is doing the heavy lifting, an approximate aromatic profile is good enough. When it is not, the profile is the product, and approximate stops being good enough. This is where the gap between a blend that reads as a cultivar and one that actually reproduces it becomes commercially visible rather than academic.
Stability gets less forgiving. Terpenes are volatile, they oxidise, and the lighter monoterpenes go first. A product whose entire value is aromatic has no cushion when the top notes drop over six months on a shelf. If you have not been rigorous about shelf stability and storage, this is when it starts costing money.
Batch variation becomes the customer’s problem. Nobody notices a slightly different terpene profile when there is 10mg of THC in the can. They notice immediately when there is not. Batch testing and consistency moves from a QA nicety to the thing the brand is actually selling.
Where beverages sit
Drinks are the most exposed format and, for the same reasons, the most interesting one. A can is a single sealed container, so the per-container cap bites hardest there.
The formulation problem is real though. Terpenes are lipophilic and resist water, which is the whole reason beverage formulation leans on emulsion work. Removing the cannabinoid does not remove that problem, it removes the thing that was masking imperfect execution.
The upside is that the functional beverage category has been moving toward botanical and adaptogenic positioning anyway. A well-built terpene-forward functional drink is not a compromised THC drink. It is a product with a larger addressable market and no 12 November problem.
On the numbers being quoted
You will see the hemp-derived THC market sized at over $28 billion, with 300,000-plus jobs and around $1.5 billion in state tax revenue at risk. Those figures come from industry sources, principally the US Hemp Roundtable, not from a government statistical agency. They may well be broadly right. They are advocacy estimates produced during a lobbying fight, and they should be attributed that way rather than repeated as established fact.
The delay, precisely
The Senate Appropriations Committee released continuing resolution text on 2 August 2026 that would move most of these restrictions to 11 December 2026. As of 2 August 2026 it had not passed either chamber.
If it lands, it buys four weeks and it reportedly does not cover cannabinoids that cannot be naturally produced by the plant. It is a scheduling change, not a change of direction, and it is attached to a funding fight that recurs in December.
Planning a product cycle around it would be a mistake. Planning a product cycle around what the category looks like when intoxication is capped is not.
About this article
Written 2 August 2026 and checked against the statute, the Federal Register and the published papers rather than against secondary coverage. Regulatory positions in this area are moving, so check the date before relying on it. Nothing here is legal, tax or medical advice.
